Agenus Company Profile (NASDAQ:AGEN)

About Agenus (NASDAQ:AGEN)

Agenus logoAgenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AGEN
  • CUSIP: 00847G70
  • Web: www.agenusbio.com
Capitalization:
  • Market Cap: $521.36 million
  • Outstanding Shares: 99,118,000
Average Prices:
  • 50 Day Moving Avg: $4.03
  • 200 Day Moving Avg: $3.88
  • 52 Week Range: $3.20 - $7.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.78
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $43.57 million
  • Price / Sales: 11.97
  • Book Value: $0.09 per share
  • Price / Book: 58.44
Profitability:
  • EBIDTA: ($85,440,000.00)
  • Net Margins: -257.79%
  • Return on Equity: -37,577.49%
  • Return on Assets: -57.26%
Debt:
  • Debt-to-Equity Ratio: 15.07%
  • Current Ratio: 3.80%
  • Quick Ratio: 3.79%
Misc:
  • Average Volume: 971,981 shs.
  • Beta: 2.03
  • Short Ratio: 9.82
 
Frequently Asked Questions for Agenus (NASDAQ:AGEN)

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) released its earnings results on Thursday, May, 4th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.14. The firm earned $26.96 million during the quarter, compared to analysts' expectations of $5.22 million. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 257.79%. View Agenus' Earnings History.

When will Agenus make its next earnings announcement?

Agenus is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Agenus.

Where is Agenus' stock going? Where will Agenus' stock price be in 2017?

4 equities research analysts have issued 1 year price targets for Agenus' shares. Their forecasts range from $5.00 to $7.00. On average, they expect Agenus' stock price to reach $6.33 in the next year. View Analyst Ratings for Agenus.

What are analysts saying about Agenus stock?

Here are some recent quotes from research analysts about Agenus stock:

  • 1. According to Zacks Investment Research, "Agenus' collaboration agreements with players like Incyte and Merck not only validate its technology platforms but also provide the company with funds. In fact, it received a boost when Merck selected its lead antibody candidate and several backup antibodies for an undisclosed checkpoint target. We are encouraged by Agenus’ efforts in developing Prophage vaccine for glioblastoma multiforme. In Mar 2017, the company undertook certain restructuring activities in order to cut costs and focus on developing key product candidates. However, with no approved product in its portfolio, Agenus is heavily dependent on collaborators for topline growth. Shares of the company have underperformed the Medical-Biomedical/Genetics industry year to date." (7/5/2017)
  • 2. Maxim Group analysts commented, "Agenus reported 2Q16 with $6.6M in revenue and a net loss of $60.2M or ($0.33)." (7/28/2016)

Who are some of Agenus' key competitors?

Who are Agenus' key executives?

Agenus' management team includes the folowing people:

  • Garo H. Armen Ph.D., Chairman of the Board, Chief Executive Officer, Founder
  • Christine M. Klaskin, Vice President - Finance
  • Karen Higgins Valentine, General Counsel, Chief Legal Officer
  • Ozer Baysal, Chief Commercial Officer, Head of HR
  • Jean-Marie Cuillerot M.D., Chief Medical Officer
  • Brian Corvese, Independent Director
  • Wadih Jordan, Independent Director
  • Shalini Sharp, Independent Director
  • Ulf Wiinberg, Independent Director
  • Timothy R. Wright, Independent Director

Who owns Agenus stock?

Agenus' stock is owned by a number of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.14%) and Quotient Investors LLC (0.05%). Company insiders that own Agenus stock include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg. View Institutional Ownership Trends for Agenus.

How do I buy Agenus stock?

Shares of Agenus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agenus' stock price today?

One share of Agenus stock can currently be purchased for approximately $5.26.


MarketBeat Community Rating for Agenus (NASDAQ AGEN)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Agenus (NASDAQ:AGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $6.33 (20.41% upside)

Analysts' Ratings History for Agenus (NASDAQ:AGEN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/6/2017HC WainwrightSet Price TargetHold$5.00LowView Rating Details
4/23/2017Maxim GroupReiterated RatingBuy$7.00MediumView Rating Details
12/1/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
8/23/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$17.00 -> $15.00N/AView Rating Details
12/31/2015Oppenheimer Holdings, Inc.Reiterated RatingPositive -> Outperform$14.00N/AView Rating Details
9/10/2015William BlairReiterated RatingBuyN/AView Rating Details
7/27/2015MLV & Co.Reiterated RatingBuy$9.00 -> $11.00N/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Agenus (NASDAQ:AGEN)
Earnings by Quarter for Agenus (NASDAQ:AGEN)
Earnings History by Quarter for Agenus (NASDAQ AGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017($0.38)N/AView Earnings Details
5/4/2017Q1 2017($0.32)($0.18)$5.22 million$26.96 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.30)($0.30)$6.01 million$5.58 millionViewListenView Earnings Details
10/27/2016Q316($0.32)($0.47)$6.15 million$4.45 millionViewListenView Earnings Details
7/28/2016Q216($0.34)($0.33)$5.12 million$6.59 millionViewListenView Earnings Details
4/28/2016Q116($0.23)($0.37)$6.74 million$5.96 millionViewListenView Earnings Details
3/3/2016Q415($0.17)($0.18)$9.39 million$7.64 millionViewListenView Earnings Details
10/27/2015Q315($0.15)($0.16)$5.71 million$6.85 millionViewListenView Earnings Details
7/23/2015Q215($0.15)($0.44)$5.71 million$6.38 millionViewListenView Earnings Details
4/23/2015Q115($0.15)($0.21)$11.66 million$3.95 millionViewN/AView Earnings Details
2/26/2015Q414($0.15)($0.18)$0.66 million$1.62 millionViewN/AView Earnings Details
10/31/2014Q314($0.15)($0.13)$1.96 million$1.56 millionViewN/AView Earnings Details
7/24/2014Q214($0.11)($0.12)$0.71 million$3.07 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)$0.01$0.55 million$0.72 millionViewN/AView Earnings Details
3/5/2014Q413($0.24)($0.16)$870.00 million$393.00 millionViewN/AView Earnings Details
10/24/2013Q313($0.27)($0.24)$736.00 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.21)($0.40)ViewN/AView Earnings Details
2/28/2013Q4 2012($0.24)($0.23)$0.72 million$1.09 millionViewN/AView Earnings Details
7/28/2011($0.05)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Agenus (NASDAQ:AGEN)
2017 EPS Consensus Estimate: ($1.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.33)($0.24)($0.29)
Q2 20172($0.34)($0.30)($0.32)
Q3 20172($0.34)($0.31)($0.33)
Q4 20171($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Agenus (NASDAQ:AGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Agenus (NASDAQ:AGEN)
Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 42.61%
Insider Trades by Quarter for Agenus (NASDAQ:AGEN)
Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)
Insider Trades by Quarter for Agenus (NASDAQ:AGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/12/2017Garo H ArmenCEOBuy100,000$3.35$335,000.00View SEC Filing  
2/14/2017Corp IncyteMajor ShareholderBuy10,000,000$6.00$60,000,000.00View SEC Filing  
9/6/2016Ulf WiinbergDirectorBuy30,000$6.29$188,700.00View SEC Filing  
5/9/2016Garo H ArmenCEOBuy100,000$3.18$318,000.00View SEC Filing  
5/5/2016Ozer BaysalInsiderBuy2,250$3.10$6,975.00View SEC Filing  
3/7/2016Garo H ArmenCEOBuy200,000$4.03$806,000.00View SEC Filing  
12/29/2015Garo H. ArmenCEOSell219,576$4.59$1,007,853.84View SEC Filing  
12/28/2015Garo H. ArmenCEOSell134,352$4.60$618,019.20View SEC Filing  
9/25/2015Charles Evan BallantyneCFOBuy10,000$5.05$50,500.00View SEC Filing  
9/25/2015Garo H ArmenCEOBuy100,000$5.03$503,000.00View SEC Filing  
4/29/2015Shahzad MalikDirectorSell1,107,377$7.11$7,873,450.47View SEC Filing  
1/9/2015Qvt Associates Gp LlcMajor ShareholderSell2,343,630$5.31$12,444,675.30View SEC Filing  
1/23/2014Karen ValentineVPSell2,850$3.50$9,975.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Agenus (NASDAQ:AGEN)
Latest Headlines for Agenus (NASDAQ:AGEN)
Source:
DateHeadline
americanbankingnews.com logoZacks: Brokerages Expect Agenus Inc. (AGEN) Will Announce Quarterly Sales of $6.49 Million
www.americanbankingnews.com - July 26 at 1:00 PM
finance.yahoo.com logoIs a Beat in Store for Agenus (AGEN) this Earnings Season?
finance.yahoo.com - July 24 at 1:40 PM
americanbankingnews.com logo Brokerages Expect Agenus Inc. (NASDAQ:AGEN) Will Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - July 24 at 12:36 PM
nasdaq.com logoIs a Beat in Store for Alexion (ALXN) this Earnings Season?
www.nasdaq.com - July 20 at 4:16 PM
finance.yahoo.com logouniQure N.V. (QURE) Shows Strength: Stock Moves 9.1% Higher
finance.yahoo.com - July 20 at 4:16 PM
finance.yahoo.com logoAgenus (AGEN) Catches Eye: Stock Moves Up 8.7% in Session
finance.yahoo.com - July 19 at 4:24 PM
americanbankingnews.com logoAgenus Inc. (NASDAQ:AGEN) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 19 at 9:00 AM
seekingalpha.com logoAgenus breaks out of brief consolidation after Glaxo shingles vaccine data-stoked up move; shares ahead 9%
seekingalpha.com - July 10 at 4:20 PM
americanbankingnews.com logoAgenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 10 at 11:14 AM
americanbankingnews.com logoAgenus Inc. (AGEN) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - July 8 at 10:52 PM
finance.yahoo.com logoAlexion Reportedly Being Investigated by HHS, Shares Slip
finance.yahoo.com - July 7 at 5:21 PM
finance.yahoo.com logoGeron Stock Up Almost 40% So Far This Year After '16 Decline
finance.yahoo.com - July 5 at 4:03 PM
americanbankingnews.com logoAgenus Inc. (AGEN) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 5 at 2:06 PM
nasdaq.com logoIs the Options Market Predicting a Spike in Agenus (AGEN) Stock? - Nasdaq
www.nasdaq.com - July 3 at 3:31 PM
fool.com logoBetter Buy: Agenus Inc. vs. Kite Pharma - Motley Fool
www.fool.com - July 3 at 3:31 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Agenus (AGEN) Stock?
finance.yahoo.com - July 3 at 3:31 PM
prnewswire.com logoGlioblastoma Multiforme Pipeline Therapeutics and Drug Profiles Analysis 2017 - RnR Market Research
www.prnewswire.com - July 3 at 6:22 AM
fool.com logoBetter Buy: Agenus Inc. vs. Kite Pharma
www.fool.com - July 2 at 8:11 AM
seekingalpha.com logoThese Two Biotech Stocks Could Move On Near Term Vaccine Catalysts
seekingalpha.com - June 30 at 3:40 PM
americanbankingnews.com logoZacks: Analysts Expect Agenus Inc. (AGEN) Will Announce Quarterly Sales of $5.29 Million
www.americanbankingnews.com - June 30 at 2:31 PM
americanbankingnews.com logoFY2021 Earnings Forecast for Agenus Inc. (AGEN) Issued By William Blair
www.americanbankingnews.com - June 29 at 1:34 PM
americanbankingnews.com logo-$0.38 EPS Expected for Agenus Inc. (AGEN) This Quarter
www.americanbankingnews.com - June 28 at 8:28 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Agenus Inc. (AGEN) Increased by William Blair
www.americanbankingnews.com - June 28 at 7:36 AM
americanbankingnews.com logoAgenus Inc. (AGEN) Expected to Post FY2020 Earnings of ($1.17) Per Share
www.americanbankingnews.com - June 27 at 3:26 PM
prnewswire.com logoAgenus to Webcast Annual Meeting of Stockholders - PR Newswire (press release)
www.prnewswire.com - June 21 at 4:07 PM
prnewswire.com logoPositive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant - PR Newswire (press release)
www.prnewswire.com - June 21 at 4:07 PM
finance.yahoo.com logoAgenus, Inc. breached its 50 day moving average in a Bullish Manner : AGEN-US : June 21, 2017
finance.yahoo.com - June 21 at 4:07 PM
finance.yahoo.com logoAgenus (AGEN) Looks Good: Stock Moves Up 9.6% in Session
finance.yahoo.com - June 21 at 4:07 PM
finance.yahoo.com logoAgenus to Webcast Annual Meeting of Stockholders
finance.yahoo.com - June 21 at 4:07 PM
finance.yahoo.com logoPositive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant
finance.yahoo.com - June 21 at 4:07 PM
finance.yahoo.com logoGSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting
finance.yahoo.com - June 21 at 4:07 PM
nasdaq.com logoAgenus (AGEN) Down 15.7% Since Earnings Report: Can It ... - Nasdaq
www.nasdaq.com - June 8 at 3:30 PM
finance.yahoo.com logoAgenus (AGEN) Down 15.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 8 at 3:30 PM
prnewswire.com logoAgenus' anti-CTLA-4 antibody shows strong safety and tolerability - PR Newswire (press release)
www.prnewswire.com - June 6 at 10:33 AM
finance.yahoo.com logoAgenus' anti-CTLA-4 antibody shows strong safety and tolerability
finance.yahoo.com - June 5 at 1:33 PM
americanbankingnews.com logo Brokerages Anticipate Agenus Inc (AGEN) Will Post Quarterly Sales of $5.19 Million
www.americanbankingnews.com - June 4 at 9:50 AM
americanbankingnews.com logo-$0.39 Earnings Per Share Expected for Agenus Inc (AGEN) This Quarter
www.americanbankingnews.com - June 2 at 7:34 AM
prnewswire.com logoAgenus to Participate at Two Upcoming Conferences in New York ... - PR Newswire (press release)
www.prnewswire.com - June 1 at 3:33 PM
finance.yahoo.com logoAgenus to Participate at Two Upcoming Conferences in New York City: Jefferies Healthcare and JMP Securities Life Sciences
finance.yahoo.com - June 1 at 3:33 PM
nasdaq.com logoNoteworthy Tuesday Option Activity: GOOG, PANW, AGEN
www.nasdaq.com - May 30 at 3:30 PM
prnewswire.com logoAgenus to present safety results for anti-CTLA-4 antibody at ASCO ... - PR Newswire (press release)
www.prnewswire.com - May 22 at 3:24 PM
finance.yahoo.com logoAgenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting
finance.yahoo.com - May 22 at 3:24 PM
finance.yahoo.com logoETFs with exposure to Agenus, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 3:24 PM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Agenus, Athersys ... - PR Newswire (press release)
www.prnewswire.com - May 19 at 3:24 PM
finance.yahoo.com logoETFs with exposure to Agenus, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 8:48 PM
americanbankingnews.com logo$5.19 Million in Sales Expected for Agenus Inc (AGEN) This Quarter
www.americanbankingnews.com - May 10 at 9:16 AM
finance.yahoo.com logoAgenus, Inc. :AGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 3:23 PM
americanbankingnews.com logo Brokerages Anticipate Agenus Inc (AGEN) Will Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - May 8 at 10:27 PM
finance.yahoo.com logoAgenus, Inc. – Value Analysis (NASDAQ:AGEN) : May 8, 2017
finance.yahoo.com - May 8 at 8:47 PM
baystreet.ca logoAgenus Stock Bounces on Q1 Report, Update
www.baystreet.ca - May 5 at 8:25 PM

Social

Chart

Agenus (AGEN) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff